METABOLISM AND DISPOSITION OF IMATINIB MESYLATE IN HEALTHY VOLUNTEERS

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Drug Metabolism And Disposition

• Publication date

  2005-10-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1124/dmd.105.004283PMID 16006570
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study.

  2005cited by this paper
• In vitro blood distribution and plasma protein binding of the tyrosine kinase inhibitor imatinib and its active metabolite, CGP74588, in rat, mouse, dog, monkey, healthy humans and patients with acute lymphatic leukaemia.

  2004cited by this paper
• Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients.

  2004influential reference
• Biliary Excretion of Imatinib Mesylate and Its Metabolite CGP 74588 in Humans

  2004influential reference
• Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules

  2004cited by this paper
• Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588

  2004cited by this paper
• Absolute Bioavailability of Imatinib (Glivec®) Orally versus Intravenous Infusion

  2004influential reference
• Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

  2003influential reference
• Practical management of patients with chronic myeloid leukemia receiving imatinib.

  2003cited by this paper
• Pharmaceutical approaches to colon targeted drug delivery systems.

  2003cited by this paper
• Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome P450 3A4 substrate, in patients with chronic myeloid leukaemia

  2003influential reference
• Pharmacology of imatinib (STI571).

  2002cited by this paper
• High-throughput quantification of the anti-leukemia drug STI571 (Gleevec) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry.

  2002cited by this paper
• Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy.

  2002cited by this paper
• Protein kinases as targets for anticancer agents: from inhibitors to useful drugs.

  2002cited by this paper
• Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors.

  2002influential reference
• Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

  2002cited by this paper
• Signal transduction pathways in sarcoma as targets for therapeutic intervention

  2001cited by this paper
• IMPACT OF CELLULAR METABOLISM ON THE BIOLOGICAL EFFECTS OF BENZO[A]PYRENE AND RELATED HYDROCARBONS†

  2001cited by this paper
• KIT activation is a ubiquitous feature of gastrointestinal stromal tumors.

  2001influential reference
• Use of a microplate scintillation counter as a radioactivity detector for miniaturized separation techniques in drug metabolism.

  2000influential reference
• Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.

  1998cited by this paper
• Metabolism of Strychnine N-Oxide and Brucine N-Oxide by Human Intestinal Bacteria

  1993cited by this paper
• Physiological Parameters in Laboratory Animals and Humans

  1993influential reference
• Drug Fate and Metabolism: Methods and Techniques

  1979cited by this paper

• Property-Based Prediction Uncovers Intestinal Excretion as an Elimination Route of Small-Molecule Drugs.

  2025cites this paper
• A Miniaturized Chemical High Throughput Experimentation Plate to Enable Late-Stage Oxidation Screening and Scale-up.

  2025cites this paper
• Disease–Drug–Drug Interaction of Imatinib in COVID‐19 ARDS: A Pooled Population Pharmacokinetic Analysis

  2025cites this paper
• Elucidating the Substrate Specificity of Cytochrome P450 Enzymes: Insights into N- and S-Containing Small-Molecule Metabolism

  2025cites this paper
• Evaluation of in vivo pharmacokinetic study of the anti-cancer drug imatinib using silkworms as an animal model.

  2024cites this paper
• Increased plasma imatinib exposure and toxicity in chronically treated GIST patients with SARS-CoV-2 infection: a case series

  2024influential citation
• Clinical pharmacokinetics and Drug-drug interactions of tyrosine-kinase inhibitors in chronic myeloid leukemia: a clinical perspective.

  2024cites this paper
• Therapeutic Drug Monitoring of Imatinib: Is There a Rationale for Also Quantifying Its Active Metabolite?

  2024cites this paper
• Tyrosine Kinase Inhibitors in Cancers: Treatment optimization - Part II.

  2024cites this paper
• Special Section on Perspective on Drug Metabolism and Disposition, Part I — Minireview Human Absorption, Distribution, Metabolism, and Excretion Studies: Origins, Innovations, and Importance S

  2023cites this paper
• Renal pharmacokinetic adaptation to cholestasis causes increased nephrotoxic drug accumulation by Mrp6 downregulation in mice.

  2023cites this paper
• High throughput LC/ESI-MS/MS method for simultaneous analysis of 20 oral molecular-targeted anticancer drugs and the active metabolite of sunitinib in human plasma

  2023cites this paper
• Prediction for Plasma Trough Concentration and Optimal Dosing of Imatinib under Multiple Clinical Situations Using Physiologically Based Pharmacokinetic Modeling

  2023cites this paper
• Recent advances in metabolism and toxicity of tyrosine kinase inhibitors.

  2022cites this paper
• Risk assessment and molecular mechanism study of drug-drug interactions between rivaroxaban and tyrosine kinase inhibitors mediated by CYP2J2/3A4 and BCRP/P-gp

  2022cites this paper
• The application of virtual therapeutic drug monitoring to assess the pharmacokinetics of imatinib in a Chinese Cancer population group.

  2022cites this paper
• Transport and metabolism of tyrosine kinase inhibitors associated with chronic myeloid leukemia therapy: a review

  2022cites this paper
• High-resolution AP-SMALDI MSI as a tool for drug imaging in Schistosoma mansoni

  2021cites this paper
• Metabolic N-Dealkylation and N-Oxidation as Elucidators of the Role of Alkylamino Moieties in Drugs Acting at Various Receptors

  2021cites this paper
• Influence of genetic polymorphisms in glutathione-S-transferases gene in response to imatinib among Brazilian patients with chronic myeloid leukemia

  2021cites this paper
• Individualized Management of Blood Concentration in Patients with Gastrointestinal Stromal Tumors

  2021cites this paper
• Physiologically‐based pharmacokinetic model predictions of inter‐ethnic differences in imatinib pharmacokinetics and dosing regimens

  2021cites this paper
• Impacts of SNPs on adverse events and trough concentration of imatinib in patients with gastrointestinal stromal tumors.

  2021cites this paper
• Development of a Sensitive and High-Throughput Assay for Simultaneous Quantification of 5 Tyrosine Kinase Inhibitors and 2 Active Metabolites in Human Plasma Using Ultra-high Performance Liquid Chromatography Coupled to Tandem Mass Spectrometry

  2021cites this paper
• Method development for determination of imatinib and its' major metabolite, N-desmethyl imatinib, in biological and environmental samples by SA-SHS-LPME and HPLC.

  2021cites this paper
• A novel workflow utilizing open-source software tools in the environmental fate studies: The example of imatinib biotransformation.

  2021cites this paper
• Study on Mutation Resistance to Imatinib in Chronic Myeloid Leukemia Patients from West India

  2021influential citation
• ABCG2 Single Nucleotide Polymorphism Affects Imatinib Pharmacokinetics in Lower Alpha-1-Acid Glycoprotein Levels in Humans

  2021cites this paper
• Interpretation of MS–MS spectra of small-molecule signal transduction inhibitors using accurate-m/z data and m/z-shifts with stable-isotope-labeled analogues and metabolites

  2021cites this paper
• Studies on the Quantification of Mutation Resistance to Specific Drug Therapy in Chronic Myeloid Leukemia patients

  2021cites this paper
• A Study of the Identification, Fragmentation Mode and Metabolic Pathways of Imatinib in Rats Using UHPLC-Q-TOF-MS/MS

  2021cites this paper
• Implementation of a Physiologically Based Pharmacokinetic Modeling Approach to Guide Optimal Dosing Regimens for Imatinib and Potential Drug Interactions in Paediatrics

  2020cites this paper
• Synthesis of imatinib, a tyrosine kinase inhibitor, labeled with carbon-14.

  2020cites this paper
• A Primer for Pharmaceutical Process Development Chemists and Analysts in Relation to Impurities Perceived to Be Mutagenic or “Genotoxic”

  2020cites this paper
• Pharmacology of tyrosine kinase inhibitors in chronic myeloid leukemia; a clinician’s perspective

  2020cites this paper
• Targeting Kinases in Fasciola hepatica: Anthelminthic Effects and Tissue Distribution of Selected Kinase Inhibitors

  2020cites this paper
• Prospective evaluation of variables affecting platelet function in patients with newly diagnosed chronic myeloid leukemia

  2020cites this paper
• Factors Influencing the Steady-State Plasma Concentration of Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors and Chronic Myeloid Leukemia

  2020cites this paper
• OTT_A_279998 13345..13355

  2020cites this paper
• Tandem mass spectrometry of small-molecule signal transduction inhibitors: Accurate-m/z data to adapt structure proposals of product ions.

  2020cites this paper
• Cerebrospinal fluid penetration of targeted therapeutics in pediatric brain tumor patients

  2020cites this paper
• Uptake Transporters of the SLC21, SLC22A, and SLC15A Families in Anticancer Therapy—Modulators of Cellular Entry or Pharmacokinetics?

  2020cites this paper
• Is There Enough Evidence to Classify Cycloalkyl Amine Substituents as Structural Alerts?

  2020cites this paper
• Metabolic Forest: Predicting the Diverse Structures of Drug Metabolites

  2020cites this paper
• Tyrosine kinase inhibitors induce mitochondrial dysfunction during cardiomyocyte differentiation through alteration of GATA4-mediated networks

  2020cites this paper
• Disease-drug and drug-drug interaction in COVID-19: Risk and assessment

  2020cites this paper
• Determination of the absolute bioavailability of oral imatinib using a stable isotopically labeled intravenous imatinib-d8 microdose

  2020cites this paper
• Computational Prediction of the Site(s) of Metabolism and Binding Modes of Protein Kinase Inhibitors Metabolized by CYP3A4

  2019cites this paper
• UPLC‐MS/MS method for the simultaneous determination of imatinib, voriconazole and their metabolites concentrations in rat plasma

  2019cites this paper
• Imatinib, sunitinib and pazopanib: From flat‐fixed dosing towards a pharmacokinetically guided personalized dose

  2019cites this paper
• Determination of serum imatinib and its' metabolite in patients chronic myeloid leukemia.

  2019cites this paper
• Histological changes of the rat liver after administration of imatinib mesylate:an experimental study

  2019cites this paper
• Multiple Molecular Mechanisms Contribute Towards In Vitro Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukaemia

  2019cites this paper
• Identifying the reactive metabolites of tyrosine kinase inhibitors in a comprehensive approach: Implications for drug‐drug interactions and hepatotoxicity

  2019cites this paper
• Pharmacogenetics and the treatment of chronic myeloid leukemia: how relevant clinically? An update.

  2018cites this paper
• Synthesis, in vitro and in vivo evaluation of 18F-fluoronorimatinib as radiotracer for Imatinib-sensitive gastrointestinal stromal tumors.

  2018cites this paper
• Refinement of In Vitro Methods for Identification of Aldehyde Oxidase Substrates Reveals Metabolites of Kinase Inhibitors

  2018cites this paper
• Pharmacology and pharmacokinetics of imatinib in pediatric patients

  2018cites this paper
• Comparative Pharmacology of Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia

  2018cites this paper
• Population Pharmacokinetics of Imatinib in Nigerians With Chronic Myeloid Leukemia: Clinical Implications for Dosing and Resistance

  2017cites this paper
• Effect of Glutathione S-transferase mu 1 (GSTM1) gene polymorphism on chronic myeloid leukemia risk and Imatinib treatment response

  2017cites this paper
• Absorption, metabolism, and excretion of [14C]ponatinib after a single oral dose in humans

  2017cites this paper
• Structural homologies between phenformin, lipitor and gleevec aim the same metabolic oncotarget in leukemia and melanoma

  2017cites this paper
• Liabilities Associated with the Formation of "Hard" Electrophiles in Reactive Metabolite Trapping Screens.

  2017cites this paper
• The importance of drug metabolites synthesis: the case-study of cardiotoxic anticancer drugs

  2017influential citation
• Insight to Pharmacokinetics of TKIs: Optimizing Practical Guidelines for Individualized Therapy.

  2017cites this paper
• Novel sulphur‐containing imatinib metabolites found by untargeted LC‐HRMS analysis

  2017influential citation
• CYP2C8 Genotype Significantly Alters Imatinib Metabolism in Chronic Myeloid Leukaemia Patients

  2017cites this paper
• Controlled release and anti-proliferative effect of imatinib mesylate loaded sporopollenin microcapsules extracted from pollens of Betula pendula.

  2017cites this paper
• Assessment of the genotoxicity of the tyrosine kinase inhibitor imatinib mesylate in cultured fish and human cells.

  2017cites this paper
• An ultra-specific and sensitive sandwich ELISA for imatinib using two anti-imatinib antibodies.

  2017cites this paper
• Safe handling of oral antineoplastic medications: Focus on targeted therapeutics in the home setting

  2017cites this paper
• Simultaneous quantification of imatinib and its main metabolite N-demethyl-imatinib in human plasma by liquid chromatography-tandem mass spectrometry and its application to therapeutic drug monitoring in patients with gastrointestinal stromal tumor.

  2017influential citation
• Off‑target effect of imatinib and nilotinib on human vitamin D3 metabolism.

  2017cites this paper
• A simple model predicts UGT-mediated metabolism

  2016cites this paper
• Urinary Dopamine as a Potential Index of the Transport Activity of Multidrug and Toxin Extrusion in the Kidney

  2016cites this paper
• A Multi-centric Bioequivalence Trial in Ph+ Chronic Myeloid Leukemia Patients to Assess Bioequivalence and Safety Evaluation of Generic Imatinib Mesylate 400 mg Tablets

  2016cites this paper
• Efficacy and Toxicity Assessment of Different Clinically Used Small Molecular Tyrosine Kinase Inhibitors by Computational Molecular Docking Method

  2016cites this paper
• Quillaja saponin: A prospective emulsifier for the preparation of solid lipid nanoparticles.

  2016cites this paper
• HPLC-UV ASSAY OF IMATINIB IN HUMAN PLASMA OPTIMIZED FOR BIOEQUIVALENCE STUDIES.

  2016cites this paper
• Regulatory aspects of human radiolabeled mass balance studies in oncology: concise review

  2016cites this paper
• GSTM1 and GSTP1, but not GSTT1 genetic polymorphisms are associated with chronic myeloid leukemia risk and treatment response.

  2016cites this paper
• Pharmacogenetics of drug transporters in modulating imatinib disposition and treatment outcomes in chronic myeloid leukemia & gastrointestinal stromal tumor patients.

  2016cites this paper
• Comparison of paper spray mass spectrometry analysis of dried blood spots from devices used for in-field collection of clinical samples

  2016cites this paper
• Impact of CYP2C8*3 polymorphism on in vitro metabolism of imatinib to N-desmethyl imatinib

  2016influential citation
• Pharmacokinetics Interaction between Imatinib and Genistein in Rats

  2015cites this paper
• Impact of CYP2C8 single nucleotide polymorphisms on in-vitro metabolism of imatinib to N-desmethyl imatinib

  2015influential citation
• Therapeutic Monitoring Of Imatinib Plasma Trough Levels in Chronic Myeloid Leukemia.

  2015cites this paper
• Predicting Effectiveness of Imatinib Mesylate in Tumors Expressing Platelet-Derived Growth Factors (PDGF-AA, PDGF-BB), Stem Cell Factor Ligands and Their Respective Receptors (PDGFR-α, PDGFR-β, and c-kit)

  2015cites this paper
• Detailed study of imatinib metabolization using high-resolution mass spectrometry.

  2015cites this paper
• Bioequivalence of a single 400-mg dose of imatinib 100-mg oral tablets and a 400-mg tablet in healthy adult Korean volunteers.

  2015cites this paper
• Therapeutic drug monitoring of imatinib, nilotinib, and dasatinib for patients with chronic myeloid leukemia.

  2015cites this paper
• Responses to Overdiagnosis in Thyroid Cancer Screening among Korean Women

  2015cites this paper
• Human hepatocyte assessment of imatinib drug-drug interactions - complexities in clinical translation.

  2015cites this paper
• Review of therapeutic drug monitoring of anticancer drugs part two--targeted therapies.

  2014cites this paper
• Clinical efficacy and safety of imatinib in the management of Ph+ chronic myeloid or acute lymphoblastic leukemia in Chinese patients

  2014cites this paper
• Role of CYP2C8 in the metabolism of montelukast and imatinib : Studies in vitro, in silico and in humans

  2014influential citation
• From the Department of Molecular Medicine and Surgery Karolinska Institutet, Stockholm, Sweden NOVEL ASPECTS OF THE MOLECULAR BIOLOGY OF GASTROINTESTINAL STROMAL TUMORS

  2014cites this paper
• Novel aspects of the molecular biology of gastrointestinal stromal tumors

  2014cites this paper
• In Silico Design of Monomolecular Drug Carriers for the Tyrosine Kinase Inhibitor Drug Imatinib Based on Calix- and Thiacalix[n]arene Host Molecules: A DFT and Molecular Dynamics Study.

  2014cites this paper